GB2581882B - WNT compositions and methods of process from serum-free culturing conditions - Google Patents

WNT compositions and methods of process from serum-free culturing conditions Download PDF

Info

Publication number
GB2581882B
GB2581882B GB2001567.3A GB202001567A GB2581882B GB 2581882 B GB2581882 B GB 2581882B GB 202001567 A GB202001567 A GB 202001567A GB 2581882 B GB2581882 B GB 2581882B
Authority
GB
United Kingdom
Prior art keywords
serum
methods
culturing conditions
free culturing
wnt compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB2001567.3A
Other languages
English (en)
Other versions
GB202001567D0 (en
GB2581882A (en
Inventor
Yuan Ping
Helms Jill
Zhu Ying
Liu Bo
Gaster Stefanie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankasa Regenerative Therapeutics Inc
Original Assignee
Ankasa Regenerative Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankasa Regenerative Therapeutics Inc filed Critical Ankasa Regenerative Therapeutics Inc
Priority to GB2216232.5A priority Critical patent/GB2610090B/en
Publication of GB202001567D0 publication Critical patent/GB202001567D0/en
Publication of GB2581882A publication Critical patent/GB2581882A/en
Application granted granted Critical
Publication of GB2581882B publication Critical patent/GB2581882B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB2001567.3A 2017-08-01 2018-08-01 WNT compositions and methods of process from serum-free culturing conditions Expired - Fee Related GB2581882B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB2216232.5A GB2610090B (en) 2017-08-01 2018-08-01 WNT compositions and methods of process from serum-free culturing conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539960P 2017-08-01 2017-08-01
US201862630448P 2018-02-14 2018-02-14
PCT/US2018/044886 WO2019028186A1 (en) 2017-08-01 2018-08-01 WNT COMPOSITIONS AND METHODS OF TREATMENT FROM SERUM-FREE CULTURE CONDITIONS

Publications (3)

Publication Number Publication Date
GB202001567D0 GB202001567D0 (en) 2020-03-18
GB2581882A GB2581882A (en) 2020-09-02
GB2581882B true GB2581882B (en) 2023-03-29

Family

ID=65234165

Family Applications (2)

Application Number Title Priority Date Filing Date
GB2001567.3A Expired - Fee Related GB2581882B (en) 2017-08-01 2018-08-01 WNT compositions and methods of process from serum-free culturing conditions
GB2216232.5A Expired - Fee Related GB2610090B (en) 2017-08-01 2018-08-01 WNT compositions and methods of process from serum-free culturing conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB2216232.5A Expired - Fee Related GB2610090B (en) 2017-08-01 2018-08-01 WNT compositions and methods of process from serum-free culturing conditions

Country Status (8)

Country Link
US (1) US20200399588A1 (https=)
EP (1) EP3661475A4 (https=)
JP (2) JP2020529845A (https=)
CN (1) CN111182880B (https=)
AU (1) AU2018309026A1 (https=)
CA (1) CA3071638A1 (https=)
GB (2) GB2581882B (https=)
WO (1) WO2019028186A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121846A1 (en) * 2017-12-19 2019-06-27 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
WO2021213623A1 (en) * 2020-04-20 2021-10-28 Pharmact Holding Ag A modified bacterial hyaluronidase polypeptide, production process, pharmaceutical compositions and their uses
CN116359367B (zh) * 2022-12-27 2023-08-25 绍兴市食品药品检验研究院 一种同位素内标高效液相色谱串联质谱法检测食品中γ-氨基丁酸的方法
US20260023050A1 (en) * 2024-07-22 2026-01-22 Waters Technologies Corporation Methods for analyzing lipid nanoparticles and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039673A1 (en) * 1997-05-30 2003-02-27 Edward Shanbrom Disinfection by particle-bound and insolubilized detergents
US6596305B1 (en) * 1993-07-08 2003-07-22 Elan Pharmaceuticals, Inc. Method of controlling the size of liposomes
US20120003222A1 (en) * 2010-06-28 2012-01-05 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same
US20160310424A1 (en) * 2013-10-02 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods for purification
WO2017132494A1 (en) * 2016-01-28 2017-08-03 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods for serum-free synthesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036175A2 (en) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
US20070072238A1 (en) * 2005-09-26 2007-03-29 Wyeth Wnt-frizzled chimera
AU2012308476B2 (en) * 2011-09-16 2016-04-14 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
WO2014066328A1 (en) * 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596305B1 (en) * 1993-07-08 2003-07-22 Elan Pharmaceuticals, Inc. Method of controlling the size of liposomes
US20030039673A1 (en) * 1997-05-30 2003-02-27 Edward Shanbrom Disinfection by particle-bound and insolubilized detergents
US20120003222A1 (en) * 2010-06-28 2012-01-05 Five Prime Therapeutics, Inc. Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules and treatments using same
US20160310424A1 (en) * 2013-10-02 2016-10-27 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods for purification
WO2017132494A1 (en) * 2016-01-28 2017-08-03 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods for serum-free synthesis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BMC Biology, vol. 12, 2014, Kumar et al, "Molecular dissection of Wnt3a-Frizzled8 interaction..." art. 44 *
FUJII et al., "PA tag: a versatile protein tagging system using a super high affinity antibody against a dodecapeptide derived from human podoplanin", Protein Expr Purif, (20140128), vol. 95, pages 240 - 247. entire document *
GE HEALTHCARE - Handbook, "Affinity Chromatography. Vol 1: Antibodies", (20160400), pages 1 - 173, April 2016, entire document *
MIHARA et al., "Active and water-soluble form of lipidated Wnt protein is maintained by a serum glycoprotein afamin/a-albumin", Elife, (20160223), vol. 5, e11621 pages 1 - 19, entire document *
PLoS ONE, vol. 7(1), 2012, Hendaoui et al, "Inhibition of Wnt/beta-catenin signaling by a soluble collagen-derived..." art. e30601 *
STETSENKO et al., "An Overview of the Top Ten Detergents Used for Membrane Protein Crystallization", Crystals, (20170701), vol. 7, pages 1 - 16, entire document *
TSUCHIYA et al., "Use of n-octyl-beta-D-thioglucoside, a new nonionic detergent, for solubilization and reconstitution of memhrane proteins", J Biochem, (19841101), vol. 96, no. 5, pages 1593 - 1597, entire document *

Also Published As

Publication number Publication date
AU2018309026A1 (en) 2020-03-12
GB202001567D0 (en) 2020-03-18
JP2024120178A (ja) 2024-09-04
GB2610090A (en) 2023-02-22
EP3661475A1 (en) 2020-06-10
CN111182880A (zh) 2020-05-19
GB2581882A (en) 2020-09-02
GB202216232D0 (en) 2022-12-14
EP3661475A4 (en) 2021-06-02
CA3071638A1 (en) 2019-02-07
JP2020529845A (ja) 2020-10-15
WO2019028186A1 (en) 2019-02-07
GB2610090B (en) 2023-05-17
US20200399588A1 (en) 2020-12-24
CN111182880B (zh) 2024-01-09

Similar Documents

Publication Publication Date Title
IL289046A (en) Preparations and methods for inhibiting antigens of a certain lineage
IL300438B1 (en) Compositions and methods for inhibiting lipoprotein A gene expression
IL273875A (en) Methods and compounds for inhibiting expression of LDHA
IL255406A0 (en) A method for growing in the culture of Acramansia
SG11202002889TA (en) Structurally-colored articles and methods of making and using structurally-colored articles
ZA201702071B (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
IL263662A (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
IL255998A (en) Preparations and methods for suppressing the expression of the hif2alpha strain
SG11201708741YA (en) Compositions and methods for biological production of methionine
EP3105327A4 (en) Compositions and methods of using microrna inhibitors
ZA202003590B (en) Process for the preparation of opicapone and intermediates thereof
GB2610090B (en) WNT compositions and methods of process from serum-free culturing conditions
IL264179B (en) Preparations that include micro-algae and methods for their preparation and uses
EP3359548A4 (en) METALLIC COMPOSITIONS AND METHODS OF MAKING THE SAME
GB201608060D0 (en) Method of culturing T cells
ES3061926T3 (en) Novel process for preparation of corticosteroids
PL3445406T3 (pl) Kompozycje i sposoby zwiększonej ekspresji genów PKLR
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
PT3368673T (pt) Composições e métodos para a produção de mirceno
SG11201803284YA (en) Novel method of use and compositions
EP3197949A4 (en) F-poss coatings and additives and methods of making same
GB201707034D0 (en) Modified microorganisms and methods for production of useful products
EP3262011A4 (en) Refractory article and method of making
ZA201801284B (en) Production of form coke
PL3445730T3 (pl) Makrokompozyty i kompozycje z kamienia i szkła oraz sposoby wytwarzania

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20240801